ACTG2

Across TCGA pan-cancer cohorts, ACTG2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTG2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ACTG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACTG2 expression acts as an unfavorable survival marker.

STAD, CESC, and SCLC are the cancer types where ACTG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	36	view →
CESC	OS	Median	II,III,IV	0.252	0.764	.008	14	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTG2–STAD (OS)

Open the STAD breakdown →